Vancouver, British Columbia — August 4, 2026 — Leads & Copy — PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced it has closed a fourth tranche of its non-brokered private placement, raising $215,000 through the issuance of 8,600,000 units at $0.025 per unit. This brings the total aggregate proceeds from all tranches of the offering to $1,000,000. The company had previously closed three tranches, raising $340,000, $245,000, and $200,000 respectively on May 12, June 12, and July 27, 2026. The current tranche follows previous announcements made on July 27, June 12, May 12, and April 22, 2026.
Each unit consists of one common share and one-half of a share purchase warrant. Each whole warrant is exercisable to purchase an additional common share at $0.05 for a period of two years from the closing of the fourth tranche. The warrants are subject to an acceleration right, where their expiry can be hastened if the daily closing price of the shares equals or exceeds $0.08 on the Canadian Securities Exchange or another recognized exchange for ten consecutive trading days. This acceleration right means the warrants could expire 30 days after the company issues a news release. The company clarified that the acceleration price was incorrectly stated as $0.10 in prior news releases and the correct acceleration price is $0.08 per share for all tranches.
In connection with the fourth tranche closing, the company paid a cash fee of $17,200 and issued 688,000 finder’s warrants to an eligible finder. These finder’s warrants are exercisable into one additional share at $0.05 per share for two years, also subject to the acceleration right.
PreveCeutical intends to utilize the gross proceeds from the fourth tranche for short loan repayments, audit, accounting and legal fees, patents, further studies and analysis of rodents and tissues, and general working capital purposes. All securities issued in relation to this tranche are subject to a hold period of four months and one day following the closing date, as per applicable securities laws.
The securities issued under the offering have not been registered under the United States Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such offer, solicitation, or sale would be unlawful.
PreveCeutical is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products. The company has five research and development programs: dual gene therapy for diabetes and obesity, the Sol-gel Program, Nature Identical™ peptides for various ailments, nonaddictive analgesic peptides as an alternative to highly addictive analgesics, and a therapeutic product for treating concussions in athletes.
Source: PreveCeutical Medical Inc.
